What the FIGO Staging System Means
When a doctor tells you the cervical cancer has been staged, they are using a classification called the FIGO system. FIGO stands for the International Federation of Gynecology and Obstetrics. The system assigns a number and letter to describe how far the cancer has grown. The 2018 revision updated several stage boundaries, especially for early-stage disease. According to the National Cancer Institute, staging guides nearly every treatment decision that follows.
Staging draws on physical examination, imaging such as MRI or CT, and sometimes surgical findings. Your stage does not change after treatment begins. That means the stage at diagnosis stays on your record, even if the cancer shrinks or grows later. If your pathology report was written before 2019, it may use slightly older FIGO 2009 criteria. Ask your care team which version applies to your case.
This article focuses on stages 1A, 1B, and 2A – the early-to-locally advanced group where treatment options differ most. Knowing what each label means can help you ask better questions before you agree to a care plan.
Stages 1A, 1B, and 2A: A Side-by-Side Look
| Axis | Stage 1A | Stage 1B | Stage 2A |
|---|---|---|---|
| Sub-stages | 1A1, 1A2 | 1B1, 1B2, 1B3 | 2A1, 2A2 |
| Size or depth threshold | Depth up to 5mm, width up to 7mm; microscopic only | Greater than 5mm deep, confined to cervix; sub-divided at 2cm and 4cm | Extends to upper two-thirds of vagina; sub-divided at 4cm |
| Standard treatment approach | Cone biopsy or LLETZ for 1A1; modified radical hysterectomy or trachelectomy for 1A2 | Radical hysterectomy plus pelvic lymph node removal, or chemoradiation; chemoradiation preferred at 1B3 | Chemoradiation (cisplatin plus external-beam radiation plus brachytherapy) for most cases |
| Fertility-sparing surgery possible | Yes, for carefully selected patients | Possible for 1B1 lesions up to 2cm with no lymph node involvement on imaging | Rarely; assessed case by case at specialized centers |
| When chemoradiation is typically added | Rarely; only if post-surgical pathology shows high-risk features | Added after surgery if high-risk features are found, or used as primary treatment for 1B3 | Primary treatment for most 2A cases |
Sources: National Cancer Institute – Cervical Cancer Treatment by Stage; Cancer Research UK – Stage 1 Cervical Cancer
Stage 1A: Cancer Visible Only Under a Microscope
Stage 1A is defined as a cancer that cannot be seen with the naked eye. A pathologist finds it by examining a tissue sample under a microscope. Cancer Research UK describes two sub-stages based on how deeply the cancer has grown into the cervical tissue.
Stage 1A1 means the cancer has grown no more than 3mm deep and no more than 7mm wide. At this depth, the risk of spread to nearby lymph nodes is very low – less than 1 percent. Treatment is often conservative. Many patients with 1A1 disease and no lymphovascular space invasion, meaning no cancer cells found inside blood or lymph vessels in the tissue sample, may be treated with a cone biopsy or a procedure called LLETZ (large loop excision of the transformation zone). Both approaches remove the abnormal tissue while leaving the uterus intact.
Stage 1A2 means the cancer has grown between 3mm and 5mm deep. This greater depth raises the possibility of lymph node involvement, though the absolute risk remains low. The National Cancer Institute lists treatment options for 1A2 that include modified radical hysterectomy or, for those wishing to preserve fertility, a radical trachelectomy – a procedure that removes the cervix but leaves the uterus in place. Radiation with brachytherapy is also an option for patients who are not candidates for surgery.
One finding that affects treatment at both 1A sub-stages is whether lymphovascular space invasion (LVSI) is present in the pathology report. If LVSI is noted, your oncologist may recommend more thorough lymph node evaluation, more extensive surgery, or adjuvant radiation – even at the earliest stage. Ask your pathologist or oncologist specifically whether LVSI was assessed and what was found.
Stage 1B: Cancer Still Inside the Cervix but Larger
Stage 1B includes cancers that have grown deeper than 5mm into the cervix but have not spread beyond it. The FIGO 2018 update divided this stage into three sub-stages based on tumor size. That size boundary matters because larger tumors carry a higher risk of spread and often require more intensive treatment.
Stage 1B1 means the tumor is larger than 5mm deep but no more than 2cm in its widest dimension. This group has the widest range of treatment options. The American Cancer Society lists two primary approaches considered equally valid at many centers: radical hysterectomy with removal of pelvic lymph nodes, or external-beam radiation therapy combined with brachytherapy and concurrent cisplatin-based chemotherapy. Survival outcomes have been similar between these approaches in most reported series, so the choice often depends on tumor location, your overall health, and whether preserving fertility is a priority.
Radical trachelectomy – the fertility-sparing cervix removal – may be offered for 1B1 tumors up to 2cm when imaging shows no lymph node involvement. This is a specialized procedure available at cancer centers with specific gynecologic oncology experience. Not every patient is a candidate, and the decision requires careful imaging review before surgery is scheduled.
Stage 1B2 means the tumor measures more than 2cm but no more than 4cm. Surgery remains an option but carries a higher chance of finding positive lymph nodes or close margins at pathology, which would then require adjuvant radiation after recovery. Many oncologists at this sub-stage move directly to chemoradiation to avoid a two-step treatment course. That question – surgery first versus radiation first – is worth discussing explicitly with your care team before a decision is finalized.
Stage 1B3 means the tumor is 4cm or larger but still contained within the cervix. At this size, chemoradiation is the standard approach at most major cancer centers. Surgery alone is generally not recommended because complete removal with clear margins is more difficult. The NCI treatment summary for cervical cancer notes that concurrent cisplatin-based chemotherapy given alongside radiation reduces the risk of death from cervical cancer by 30 to 50 percent compared with radiation alone. That finding shaped the current standard of care and is why chemoradiation is preferred over radiation alone from stage 1B3 onward.
Stage 2A: Cancer Reaching the Upper Vagina
Stage 2A means the cancer has grown beyond the cervix into the upper two-thirds of the vagina. It has not yet reached the tissues around the uterus (called the parametria) or the pelvic wall. This distinction matters clinically: parametrial involvement moves the diagnosis to stage 2B, which typically rules out primary surgery at most centers.
Stage 2A is divided into two sub-stages. Stage 2A1 means the tumor is 4cm or smaller at its widest point. Stage 2A2 means it is larger than 4cm. Both sub-stages are treated primarily with chemoradiation in most guidelines, though 2A1 may be considered for surgery at specialized centers with extensive gynecologic oncology experience and when imaging clearly shows no lymph node involvement.
The chemoradiation regimen for stage 2A typically combines external-beam pelvic radiation with two or more sessions of intracavitary brachytherapy – a form of internal radiation that delivers a high dose directly to the tumor bed. Cisplatin is the most commonly used concurrent chemotherapy agent. The American Cancer Society notes that this combined approach is standard across stages 1B3 and 2A for most patients. After chemoradiation, some teams recommend additional chemotherapy cycles, though practice varies by center and is an active area of clinical investigation.
How Doctors Choose Between Surgery and Radiation
For early cervical cancer – particularly stages 1A2 through 1B2 – both surgery and chemoradiation may achieve comparable outcomes in many patients. The choice between them depends on several factors.
- Tumor size and location – Larger or centrally placed tumors may be harder to remove with clear margins.
- Lymph node status – If imaging or a sentinel lymph node procedure shows involved nodes, chemoradiation is usually preferred.
- Desire to preserve fertility – Only surgery (trachelectomy) offers a path to future pregnancy. Radiation permanently affects ovarian function and uterine capacity.
- Ovarian conservation – Surgical patients may have their ovaries moved out of the radiation field before adjuvant radiation, a procedure called ovarian transposition. This step helps preserve hormonal function in younger patients.
- Overall health – Patients with conditions that raise surgical risk may be better served by radiation-based treatment.
- Center experience – Radical trachelectomy and pelvic lymphadenectomy require surgical teams with specific training. Outcomes at high-volume centers tend to be more consistent.
Neither surgery nor chemoradiation is universally superior across all patients and stages. What matters is that the plan chosen fits your specific tumor, your pathology findings, and your health goals.
Fertility Preservation: What to Know Before Treatment Starts
For patients diagnosed at stage 1A1, 1A2, or small 1B1, preserving the ability to carry a future pregnancy may be possible. The key procedure is radical trachelectomy, which removes the cervix and surrounding tissue while leaving the body of the uterus. A cervical cerclage – a supportive stitch – is placed to help maintain a future pregnancy.
The procedure is not appropriate for everyone. Guidelines generally limit trachelectomy to tumors no larger than 2cm, no lymph node involvement on imaging, and certain tumor types. Pregnancy after trachelectomy is possible but carries some additional risk of preterm birth. If you are considering this option, a referral to a gynecologic oncologist who performs trachelectomies regularly is an important step.
If chemoradiation is your treatment path, ovarian function will be affected. Egg or embryo preservation before treatment begins is worth discussing with a reproductive specialist as soon as possible after diagnosis, since the window before treatment starts is narrow. Some cancer centers have rapid-access fertility preservation programs for patients with newly diagnosed cervical cancer.
If you are already through initial treatment and managing ongoing surveillance, an article on managing pap smear anxiety after cervical cancer reviews strategies other survivors have found useful. And if your plan includes pelvic radiation and you want to understand integrative options for radiation-related side effects, this guide on Boswellia for pelvic lymphedema after cervical cancer radiation reviews the available evidence on Boswellia serrata AKBA for post-radiation inflammation.
Questions Worth Asking Before Treatment Begins
- Which FIGO 2018 sub-stage does my pathology report place me in – and what does that mean for my specific treatment options?
- Does my report mention lymphovascular space invasion (LVSI) or positive margins? How does that change the recommendation?
- What imaging was done to evaluate my lymph nodes – and are the nodes clear on that imaging?
- Is fertility preservation surgically possible given my specific tumor size, location, and histologic type?
- If surgery is recommended, what is the estimated chance I will also need radiation afterward – and what does a two-treatment course mean for my recovery?
- What clinical trials are open for my stage at this center?
Writing questions down before each appointment and keeping notes during the visit can help you retain what is discussed. A second opinion from another gynecologic oncologist is reasonable at any point in the decision process.
Integrative Support Alongside Standard Treatment
Some patients at every stage of cervical cancer ask about integrative approaches that may support wellbeing during and after treatment. Evidence quality varies widely across these options, and none replaces surgery, radiation, or chemotherapy. If you are exploring this area, you can find formulations that list ingredients and doses clearly, so you can have an informed conversation with your care team before adding anything to your routine.
If you are on any prescription medication, pregnant, or breastfeeding, speak with your clinician before starting any supplement or over-the-counter product. This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
